A Reversal for Cue Biopharma Inc (NASDAQ:CUE) Is Not Near. The Stock Has Rise in Shorts

May 24, 2018 - By Migdalia James

The stock of Cue Biopharma Inc (NASDAQ:CUE) registered an increase of 4.81% in short interest. CUE’s total short interest was 401,300 shares in May as published by FINRA. Its up 4.81% from 382,900 shares, reported previously. With 42,500 shares average volume, it will take short sellers 9 days to cover their CUE’s short positions. The short interest to Cue Biopharma Inc’s float is 5.11%.

The stock decreased 2.09% or $0.29 during the last trading session, reaching $13.41. About 4,012 shares traded. Cue Biopharma, Inc. (NASDAQ:CUE) has 0.00% since May 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. The company has market cap of $270.04 million. The Company’s lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. It currently has negative earnings. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells.

More recent Cue Biopharma, Inc. (NASDAQ:CUE) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Karyopharm’s STORM Study, Inogen Rallies On Earnings” on May 01, 2018. Also Globenewswire.com published the news titled: “Cue Biopharma to Host Investor Business Update Call and Webcast” on May 10, 2018. Nasdaq.com‘s news article titled: “Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer” with publication date: April 25, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: